2 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Antipsychotic-induced Weight Gain (AIWG): new trials by email Literature Review of Antipsychotic-induced Weight Gain (AIWG) trials Research Report on Antipsychotic-induced Weight Gain (AIWG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial Dapagliflozin, Metformin, Common Lifestyle Program - Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain | Phase 4 | Not yet recruiting | Sultan Qaboos University | 110 | 2026-09-01 | 2026-06-10 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) Miricorlilant, Placebo - Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Completed | Corcept Therapeutics | 150 | 2020-09-09 | 2024-06-13 |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications Miricorilant, Placebo - Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Completed | Corcept Therapeutics | 71 | 2019-12-04 | 2024-09-19 |
Mental Disorders (2) · Obesity (2) · Schizophrenia (2) · Weight Gain (2) · Bipolar Disorder (1) · Psychotic Disorders (1)
Schizophrenia Spectrum and Other Psychotic Disorders (3) · Body Weight (2) · Body Weight Changes (2) · Nutrition Disorders (2) · Nutritional and Metabolic Diseases (2) · Overnutrition (2) · Overweight (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Bipolar and Related Disorders (1) · Mental Disorders (1) · Mood Disorders (1)
CORT118335 (2) · Metformin (1) · dapagliflozin (1)
Corcept Therapeutics (2) · Sultan Qaboos University (1)
United States (2) · Oman (1)
Kavita Juneja, MD (2) · Mohammed Al Alawi, MD, PhD (1)